Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP1381418.RALQzc4qJZ6svUZfiI1GGqXwNSUu_5x8Vk5JbNvBKOuCM130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP1381418.RALQzc4qJZ6svUZfiI1GGqXwNSUu_5x8Vk5JbNvBKOuCM130_assertion type Assertion NP1381418.RALQzc4qJZ6svUZfiI1GGqXwNSUu_5x8Vk5JbNvBKOuCM130_head.
- NP1381418.RALQzc4qJZ6svUZfiI1GGqXwNSUu_5x8Vk5JbNvBKOuCM130_assertion description "[Expression and functional activity of P-glycoprotein (P-gp) were measured in 182 acute myelogenous leukemia (AML) patients: 136 patients were treated with the AML-6 protocol (EORTC), containing daunorubicin, vincristine, and conventional-dose cytarabine (ara-C), and 21 patients received idarubicin, vepeside, and conventional-dose ara-C (ICE-AML-10 protocol/EORTC).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1381418.RALQzc4qJZ6svUZfiI1GGqXwNSUu_5x8Vk5JbNvBKOuCM130_provenance.
- NP1381418.RALQzc4qJZ6svUZfiI1GGqXwNSUu_5x8Vk5JbNvBKOuCM130_assertion evidence source_evidence_literature NP1381418.RALQzc4qJZ6svUZfiI1GGqXwNSUu_5x8Vk5JbNvBKOuCM130_provenance.
- NP1381418.RALQzc4qJZ6svUZfiI1GGqXwNSUu_5x8Vk5JbNvBKOuCM130_assertion SIO_000772 9322679 NP1381418.RALQzc4qJZ6svUZfiI1GGqXwNSUu_5x8Vk5JbNvBKOuCM130_provenance.
- NP1381418.RALQzc4qJZ6svUZfiI1GGqXwNSUu_5x8Vk5JbNvBKOuCM130_assertion wasDerivedFrom befree-2016 NP1381418.RALQzc4qJZ6svUZfiI1GGqXwNSUu_5x8Vk5JbNvBKOuCM130_provenance.
- NP1381418.RALQzc4qJZ6svUZfiI1GGqXwNSUu_5x8Vk5JbNvBKOuCM130_assertion wasGeneratedBy ECO_0000203 NP1381418.RALQzc4qJZ6svUZfiI1GGqXwNSUu_5x8Vk5JbNvBKOuCM130_provenance.